Watch out, Pfizer and Moderna; Anti-aging breakthrough in mice?; Neuro for the new GSK; and more – Endpoints News

When GlaxoSmithKline R&D chief Hal Barron outlined his vision for the new GSK, he touted repeatedly how, digging through functional genomic datasets from partners like 23andMe and the UK Biobank, his team could see things that others can’t and propose or validate hypotheses in a whole new way.

And that can sometimes take them in a surprising direction.

GSK is dropping a whopping $700 million upfront to kickstart an alliance with Alector — the San Francisco biotech helmed by Genentech vet Arnon Rosenthal — that could spawn another $1.5 billion in milestones if the two antibodies at its center clear all tests in a range of notorious neurodegenerative diseases including Alzheimer’s, Parkinson’s, amyotrophic lateral sclerosis and frontotemporal dementia.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 110,900+ biopharma pros reading Endpoints daily — and it’s free.

Spread the love

Leave a Reply

Your email address will not be published.